23 11, 2022

Qkine and 3D Bio-Tissues collaboration awarded €100,000 at EIT Food Venture Summit 2022

By |2022-11-23T06:46:58+00:00November 23rd, 2022|awards, cellular agriculture, news, press release|Comments Off on Qkine and 3D Bio-Tissues collaboration awarded €100,000 at EIT Food Venture Summit 2022

A collaboration between Qkine and 3D Bio-Tissues has been awarded one of four prestigious prizes at the 2022 EIT Food Venture Summit, held in Lisbon, Portugal. Prize money will be used to develop new solutions to reduce the cost of cultivated meat.

10 01, 2022

the 5th anniversary of Qkine

By |2022-01-10T09:30:43+00:00January 10th, 2022|cellular agriculture, news, protein science, resources, stem cells|Comments Off on the 5th anniversary of Qkine

There has been an impressive drive towards innovation in stem cell protocols this year. As 2021 comes to a close, we reflect on the highlights for stem cell science over the year. It was great to see new culture media, such as B8 and “Beefy-9”, published, developments in cultivated meat science hit the news and iPSC-based therapies edge closer to the clinic. Reproducibility remains the underlying theme, and indeed requirement, for maximising the impact of these wonderful developments and at Qkine we’ll continue to do everything we can to help in 2022.

10 09, 2021

Qkine earns ISO9001: 2015 certification for protein R&D and manufacture facilities in Cambridge, UK

By |2021-09-10T18:53:50+00:00September 10th, 2021|awards, cellular agriculture, news, press release, quality|Comments Off on Qkine earns ISO9001: 2015 certification for protein R&D and manufacture facilities in Cambridge, UK

Qkine certified ISO9001: 2015 for its quality management system encompassing R&D, manufacturing, and operations in Cambridge, UK. Qkine supplies growth factors and cytokines to the fast-moving stem cell, organoid and emerging cultured meat sectors. Exceptional product quality and scientific support are crucial to customer's business processes and experimental outcomes.

26 07, 2021

Qkine and Enantis sign licensing deal for hyperstable FGF2-STAB®

By |2021-07-26T08:14:57+00:00July 26th, 2021|animal-free, cellular agriculture, news, press release, protein engineering, protein science, stem cells|Comments Off on Qkine and Enantis sign licensing deal for hyperstable FGF2-STAB®

Qkine and Enantis have concluded a global licensing deal for Enantis’s patented FGF2-STAB® technology. FGF2-STAB® is a hyperstable form of FGF-2 (bFGF), a core reagent for stem cell culture. FGF2-STAB (FGF2-G3) does not degrade in culture media for enhanced weekend-free stem cell culture media and advanced chemically defined systems, such as those needed in the cultured meat industry.

Title

Go to Top